Literature DB >> 36076098

Cardiopulmonary Exercise Testing Characterizes Silent Cardiovascular Abnormalities in Asymptomatic Pediatric Cancer Survivors.

Takeshi Tsuda1,2, Daphney Kernizan3, Austin Glass3,4, Gina D'Aloisio3, Jobayer Hossain5, Joanne Quillen6.   

Abstract

Late-onset cardiovascular complications are serious concerns for pediatric cancer survivors (PCS) including those who are asymptomatic. We investigated whether cardiopulmonary exercise testing (CPET) can delineate the underlying pathophysiology of preclinical cardiovascular abnormalities in PCS. We examined CPET data via cycle ergometer in asymptomatic PCS with normal echocardiogram and age-matched controls. Peak and submaximal parameters were analyzed. Fifty-three PCS and 60 controls were studied. Peak oxygen consumption (VO2), peak work rate (WR), and ventilatory anaerobic threshold (VAT) were significantly lower in PCS than controls (1.86 ± 0.53 vs. 2.23 ± 0.61 L/min, 125 ± 45 vs. 154 ± 46 W, and 1.20 ± 0.35 vs. 1.42 ± 0.43 L/min, respectively; all p < 0.01), whereas peak heart rate (HR) and ventilatory efficiency (a slope of minute ventilation over CO2 production or ∆VE/∆VCO2) were comparable. Peak respiratory exchange ratio (RER) was significantly higher in PCS (p = 0.0006). Stroke volume (SV) reserve was decreased in PCS, indicated by simultaneous higher dependency on HR (higher ∆HR/∆WR) and lower peak oxygen pulse (OP). Twelve PCS with high peak RER (≥ 1.3) revealed lower pVO2 and VAT than the rest of PCS despite higher ventilatory efficiency (lower ∆VE/∆VCO2), suggesting fundamental deficiency in oxygen utilization in some PCS. Poor exercise performance in PCS may be mainly attributed to limited stroke volume reserve, but the underlying pathophysiology is multifactorial. Combined assessment of peak and submaximal CPET parameters provided critical information in delineating underlying exercise physiology of PCS.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cancer treatment; Cardiotoxicity; Exercise performance; Peak oxygen consumption (pVO2); Preclinical; Submaximal exercise

Year:  2022        PMID: 36076098     DOI: 10.1007/s00246-022-02995-w

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.838


  40 in total

1.  Paediatric cardio-oncology: epidemiology, screening, prevention, and treatment.

Authors:  Eric J Chow; Kasey J Leger; Neel S Bhatt; Daniel A Mulrooney; Colin J Ross; Sanjeev Aggarwal; Neha Bansal; Matthew J Ehrhardt; Saro H Armenian; Jessica M Scott; Borah Hong
Journal:  Cardiovasc Res       Date:  2019-04-15       Impact factor: 10.787

2.  Subclinical cardiac dysfunction and exercise performance in childhood cancer survivors.

Authors:  Enrico De Caro; Attilio Smeraldi; Gianluca Trocchio; Mariagrazia Calevo; Guia Hanau; Giacomo Pongiglione
Journal:  Pediatr Blood Cancer       Date:  2011-01       Impact factor: 3.167

3.  Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia.

Authors:  Steven E Lipshultz; Stuart R Lipsitz; Stephen E Sallan; Virginia M Dalton; Suzanne M Mone; Richard D Gelber; Steven D Colan
Journal:  J Clin Oncol       Date:  2005-04-20       Impact factor: 44.544

4.  Cardiopulmonary Aerobic Fitness Assessment During Maximal and Submaximal Exercise Testing in Pediatric Oncology Patients After Chemotherapy.

Authors:  Adam W Powell; Rajaram Nagarajan; Wayne A Mays; Clifford Chin; Timothy K Knilans; Sandra K Knecht; Michelle A Amos; Yvette M Gerdes; Thomas D Ryan
Journal:  Am J Clin Oncol       Date:  2018-11       Impact factor: 2.339

5.  Oxygen uptake efficiency slope: a new index of cardiorespiratory functional reserve derived from the relation between oxygen uptake and minute ventilation during incremental exercise.

Authors:  R Baba; M Nagashima; M Goto; Y Nagano; M Yokota; N Tauchi; K Nishibata
Journal:  J Am Coll Cardiol       Date:  1996-11-15       Impact factor: 24.094

6.  Occult cardiotoxicity in childhood cancer survivors exposed to anthracycline therapy.

Authors:  Olga H Toro-Salazar; Eileen Gillan; Michael T O'Loughlin; Georgine S Burke; Joanna Ferranti; Jeffrey Stainsby; Bruce Liang; Wojciech Mazur; Subha V Raman; Kan N Hor
Journal:  Circ Cardiovasc Imaging       Date:  2013-10-04       Impact factor: 7.792

7.  Exercise capacity in long-term survivors of pediatric cancer: an analysis from the Cardiac Risk Factors in Childhood Cancer Survivors Study.

Authors:  Angela M Miller; Gabriela Lopez-Mitnik; Gabriel Somarriba; Stuart R Lipsitz; Andrea S Hinkle; Louis S Constine; Steven E Lipshultz; Tracie L Miller
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

Review 8.  Survivors of childhood and adolescent cancer: life-long risks and responsibilities.

Authors:  Leslie L Robison; Melissa M Hudson
Journal:  Nat Rev Cancer       Date:  2013-12-05       Impact factor: 60.716

9.  Impaired Left Ventricular Reserve in Childhood Cancer Survivors Treated With Anthracycline Therapy.

Authors:  Sachie Kaneko; Edythe B Tham; Mark J Haykowsky; Maria Spavor; Nee S Khoo; Andrew S Mackie; Jeffrey F Smallhorn; Richard B Thompson; Michael D Nelson
Journal:  Pediatr Blood Cancer       Date:  2016-02-04       Impact factor: 3.167

10.  Chronic health conditions in adult survivors of childhood cancer.

Authors:  Kevin C Oeffinger; Ann C Mertens; Charles A Sklar; Toana Kawashima; Melissa M Hudson; Anna T Meadows; Debra L Friedman; Neyssa Marina; Wendy Hobbie; Nina S Kadan-Lottick; Cindy L Schwartz; Wendy Leisenring; Leslie L Robison
Journal:  N Engl J Med       Date:  2006-10-12       Impact factor: 176.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.